Candel Therapeutics (CADL) Non-Current Deffered Revenue (2020 - 2023)
Historic Non-Current Deffered Revenue for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $108000.0.
- Candel Therapeutics' Non-Current Deffered Revenue changed N/A to $108000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $108000.0, marking a year-over-year change of. This contributed to the annual value of $144000.0 for FY2022, which is 8389.26% down from last year.
- According to the latest figures from Q3 2023, Candel Therapeutics' Non-Current Deffered Revenue is $108000.0.
- In the past 5 years, Candel Therapeutics' Non-Current Deffered Revenue ranged from a high of $894000.0 in Q4 2021 and a low of $108000.0 during Q3 2023
- For the 4-year period, Candel Therapeutics' Non-Current Deffered Revenue averaged around $395625.0, with its median value being $349000.0 (2021).
- Per our database at Business Quant, Candel Therapeutics' Non-Current Deffered Revenue surged by 4145.57% in 2021 and then plummeted by 8389.26% in 2022.
- Quarter analysis of 4 years shows Candel Therapeutics' Non-Current Deffered Revenue stood at $632000.0 in 2020, then surged by 41.46% to $894000.0 in 2021, then crashed by 83.89% to $144000.0 in 2022, then decreased by 25.0% to $108000.0 in 2023.
- Its last three reported values are $108000.0 in Q3 2023, $120000.0 for Q2 2023, and $132000.0 during Q1 2023.